AI / data analytics / healthtech / informatics

Evaluating future drug candidates and their manufacture together By Professor Peter Dunnill Classically, evaluating a candidate drug has preceded evaluation of the process for making it. The late rush to process development worked reasonably well with simple chemical pharmaceuticals. With complex biopharmaceuticals, a new approach is needed. One now being developed has implications for increasingly […]

Chemogenomics – A gene family approach to parallel drug discovery By Dr Paul R. Caron, Dr Michael D. Mullican, Dr Robert D. Mashal, Dr Keith P. Wilson, Dr Michael S. Su and Dr Mark A. Murcko Currently available drugs only target around 500 different proteins (4). Recent reports from efforts to sequence the human genome […]

The lab on a chip and its impact on drug discovery by Dr Simon Cowen and Dr Coulton Legge Few technology developments have had as profound an effect on society as the invention of the microchip integrated circuit in the 1960s. Since then, the power of electronic circuits has increased while their cost in real […]

Why pharmaceutical companies should teach scientists to be entrepreneurs By Dr Jeffrey P. Kiplinger Conventional wisdom says that big employers do not want anything to do with entrepreneurs as employees. The last thing a human resources director wants to see on a resume is that a candidate started a business and failed. The suspicion is […]

The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far more effectively, using novel delivery […]

Health economic considerations for early drug discovery By Dr Ann-Marie Craig and Dr Lisa Kennedy The use of health economics in early phase development, while not an exact science, can, when conjoined with clinical evidence, be a very valuable information tool enabling companies to identify whether there is a market worth pursuing while identifying issues […]

Stem Cells – The long march forward to the clinic By Dr Alan Colman The area of cellular therapeutics has never been readily embraced by ‘Big Pharma’, with ethical and regulatory issues even more complex and troublesome than proteins. Can stem cell therapy provide the key to unlocking a rich vein of pharmaceutical activity? In […]

Outsourcing life science informatics solutions By Dr Steve Gardner The life science industry depends on information gathered from new technologies for productivity and competitive advantage in the R&D process. As more information is gathered and the systems become more complex, building and maintaining data management solutions that support rapid and accurate decision-making becomes harder. This […]

By Dr Doros Platika As the population ages, the scientific and medical communities are working to solve the challenges this changing demographic will place on society. Companies involved in the promising field of regenerative medicine are now on the cutting edge as it strives to promote longevity without disability. Regenerative medicine offers hope and promise […]

Protein Therapeutics – New ladders up the fruit tree By Dr Richard AG Smith Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or – in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics – simply passe. This article […]